SoftWave — Joint Pain Specialists

SoftWave

About SoftWave

Next-generation
shockwave therapy

SoftWave uses soundwaves to recruit your body's own stem cells to the injury site to reduce pain and start healing essentially immediately. SoftWave has the patent for the only "non-focused" shockwave therapy in the world — and it's the only shockwave therapy device approved to treat wounds at amazing speeds. There are levels to shockwave therapy, and SoftWave is at the top.

#1 Shockwave
in the world

Peer-Reviewed Research

Effect of shock waves on macrophages: tissue regeneration & remodeling

Introduction

Extracorporeal Shock Wave Therapy (ESWT) is broadly used as a non-surgical therapy in various diseases for its pro-angiogenic and anti-inflammatory effects. As macrophages take part in both the onset and amplification of the inflammatory response, we investigated the effect of SW on their biology.

Methods

Human monocyte-derived macrophages were polarized to classic (M1) pro-inflammatory or alternative (M2) anti-inflammatory macrophages, then exposed to SW at different intensities. Marker gene expression was measured by qPCR at multiple time points.

ResultLow energy SW caused significant inhibition of M1 pro-inflammatory marker genes (CD80, COX2, CCL5)

ResultSynergistic effect for M2 anti-inflammatory marker genes (ALOX15, MRC1, CCL18)

CytokinesSignificant increase in IL-10 (anti-inflammatory)

CytokinesSignificant reduction in IL-1β (pro-inflammatory)

Clinical Study

Shock wave therapy for acute & chronic soft tissue wounds: a feasibility study

Background

Nonhealing wounds are a major, functionally-limiting medical problem. Various studies report complete wound epithelialization of 48–56% over 30–65 days with different treatment modalities. Extracorporeal shock wave therapy (ESWT) may accelerate and improve wound repair.

208 patients with complicated, nonhealing, acute and chronic soft-tissue wounds were prospectively enrolled between August 2004 and June 2006.

208

patients

prospectively enrolled

75%

achieved 100% wound epithelialization

toxicity

no treatment-related adverse events

Results — Of 208 patients enrolled, 156 (75%) achieved 100% wound epithelialization. During a mean follow-up of 44 days, there was no treatment-related toxicity, infection, or deterioration of any ESWT-treated wound.

Conclusions — The ESWT strategy is feasible and well tolerated by patients with acute and chronic soft tissue wounds. Shock wave therapy is being evaluated in a Phase III trial for acute traumatic wounds.

Watch

SoftWave Video Overview

Watch a quick walkthrough of how SoftWave works and what to expect during treatment.

Emerging Treatment

Extracorporeal Shock Wave Therapy: An Emerging Treatment Modality for Retracting Scars of the Hands

Prolonged and abnormal scarring after trauma, burns, and surgical procedures often results in a pathologic scar. We evaluated the efficacy of unfocused shock wave treatment, alone or in combination with manual therapy, on retracting scars on the hands. Scar appearance was assessed by the modified Vancouver Scar Scale; functional hand mobility by a range-of-motion scale; and a visual analogue score was used for improvements in referred pain. For each active treatment group, statistically significant improvements were recorded as early as five treatment sessions and confirmed 2 weeks after the last session. Histopathological examination revealed significant increases in dermal fibroblasts, neoangiogenetic response, and type-I collagen concentration.

Vancouver Scar Scale

Significant improvement after just 5 sessions

Range of Motion

Functional mobility restored and confirmed at follow-up

Pain Reduction

Visual analogue scores show meaningful pain relief

Collagen Type I

Significant increase confirmed by histopathology